Guggenheim analyst Michael Schmidt upgraded Mersana Therapeutics to Buy from Neutral with a $7 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MRSN:
- Mersana Therapeutics Shares Corporate Presentation Update
- Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
- Mersana Therapeutics to Present at Upcoming Investor Conferences
- Mersana Therapeutics (MRSN) Q4 Earnings Cheat Sheet
- Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024